The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|November 20, 2013
Equipment and Processing Report
- Equipment and Processing Report-11-20-2013
- Volume 0
- Issue 0
November 2013 Editor's Picks: Products from Pall and I Holland
Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report
Pall
A single-use system provides flexible automation for biopharmaceutical manufacturing.
I Holland
Tablet-tooling coating improves punch and die performance
Articles in this issue
almost 13 years ago
Operational Excellence Improves Quality and Compliancealmost 13 years ago
Tracking Biopharmaceutical Manufacturing Facility Trendsalmost 13 years ago
Serialization Efforts Move ForwardRelated to this article
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.